Medarex
16
0
0
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
18.8%
3 terminated/withdrawn out of 16 trials
80.0%
-6.5% vs industry average
6%
1 trials in Phase 3/4
58%
7 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
Role: collaborator
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
Role: collaborator
A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma
Role: collaborator
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
Role: collaborator
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
Role: collaborator
A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)
Role: collaborator
A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Role: collaborator
A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide
Role: collaborator
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
Role: collaborator
Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma
Role: collaborator
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
Role: collaborator
Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine
Role: collaborator
Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer
Role: collaborator
Ph1 Study of Valortim and Doxycycline in Humans
Role: collaborator
Ph1 Study of Valortim and Ciprofloxacin in Humans
Role: collaborator
Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Role: collaborator
All 16 trials loaded